Synairgen (LON:SNG) Share Price Passes Below Two Hundred Day Moving Average of $22.44
Synairgen (LON:SNG) Share Price Passes Below Two Hundred Day Moving Average of $22.44
Synairgen plc (LON:SNG – Get Rating)'s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 22.44 ($0.27) and traded as low as GBX 11 ($0.13). Synairgen shares last traded at GBX 12.50 ($0.15), with a volume of 990,485 shares.
在週五的交易中，Synairgen plc(倫敦股票代碼：SNG-GET Rating)的股價跌破了200日移動均線。該股的200日移動均線為22.44英鎊(0.27美元)，交易價格低至11英鎊(0.13美元)。Synairgen的股票最新交易價格為12.50英鎊(0.15美元)，成交量為990,485股。
Synairgen Stock Down 13.8 %
Synairgen股價下跌13.8%
The business's fifty day simple moving average is GBX 18.24 and its 200 day simple moving average is GBX 22.44. The stock has a market cap of £25.17 million and a price-to-earnings ratio of -0.51. The company has a current ratio of 6.35, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09.
該業務的50日簡單移動均線切入位為18.24,200日簡單移動均線切入位為22.44。該股市值為2517萬GB，本益比為-0.51。該公司的流動比率為6.35，速動比率為6.35，債務權益比率為0.09。
Synairgen Company Profile
Synairgen公司簡介
(Get Rating)
(獲取評級)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc發現和開發治療呼吸系統疾病的藥物。該公司開發的產品有：治療新冠肺炎的乙型吸入型幹擾素SG001；治療感冒和流感引起的哮喘的乙型幹擾素吸入劑；治療或預防慢性阻塞性肺病的乙型幹擾素第二階段臨床試驗；以及治療特發性肺纖維化的LXL2抑制劑。
Read More
閱讀更多內容
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- MarketBeat：回顧一週12/19-12/23
- 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
- 通脹降溫，標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synairgen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Synairgen和相關公司的最新新聞和分析師評級的每日簡明摘要。